4-甲氧基哌啶-1-磺酰氯化 | 355849-73-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 中文名称: 4-甲氧基哌啶-1-磺酰氯化
• 英文名称: 4-Methoxypiperidine-1-sulfonyl chloride
• CAS: 355849-73-9
• 化学式: C₆H₁₂ClNO₃S
• 分子量: 213.68
• InChiKey: QQHWNEIDFLVBBS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  55
• 氢给体数：
  0
• 氢受体数：
  4

安全信息

• 海关编码：
  2933399090

文献信息

• [EN] HETEROARYLBENZIMIDAZOLE COMPOUNDS<br/>[FR] COMPOSÉS HÉTÉROARYLBENZIMIDAZOLE
  申请人：BAYER PHARMA AG

  公开号：WO2017102091A1

  公开（公告）日：2017-06-22

  The present invention covers heteroarylbenzimidazole compounds of general formula (I) in which R1, R2, R3, R4 and R5 are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of hyperproliferative and/or inflammatory disorders, as a sole agent or in combination with other active ingredients.

  本发明涵盖了一般式（I）中的杂环芳基苯并咪唑化合物，其中R1、R2、R3、R4和R5如本文所定义，制备所述化合物的方法，用于制备所述化合物的有用中间体化合物，包括所述化合物的药物组合物和组合物，以及利用所述化合物制造用于治疗或预防疾病的药物组合物，特别是治疗或预防过度增殖和/或炎症性疾病的药物组合物，作为唯一活性成分或与其他活性成分组合使用。
• [EN] OXADIAZOLE COMPOUNDS<br/>[FR] COMPOSÉS D'OXADIAZOLE
  申请人：REMYND NV

  公开号：WO2015140130A1

  公开（公告）日：2015-09-24

  The present invention relates to a compound of formula (I) or (II) or a stereoisomer, enantiomer, racemic, or tautomer thereof, (I) (II) wherein R1,R2,R3,L1,L2,L3,L4,L5 and n, have the same meaning as that defined in the claims and the description. The present invention also relates to compositions, in particular pharmaceuticals, comprising such compounds, and to uses of such compounds and compositions for the prevention and/or treatment of metabolic disorders and/or neurodegenerative diseases, and/or protein misfolding disorders.

  本发明涉及式(I)或(II)的化合物或其立体异构体、对映体、消旋体或互变异构体，其中R1、R2、R3、L1、L2、L3、L4、L5和n的含义与权利要求和说明中定义的含义相同。本发明还涉及包含这些化合物的组合物，特别是药物，以及利用这些化合物和组合物预防和/或治疗代谢紊乱和/或神经退行性疾病和/或蛋白质错折性疾病的用途。
• Thiazepinyl hydroxamic acid derivatives as matrix metalloproteinase inhibitors
  申请人：——

  公开号：US20030134849A1

  公开（公告）日：2003-07-17

  A compound of formula (I) in which R 1 is halo, lower alkoxy, optionally substituted aryl, optionally substituted aryloxy, optionally substituted heterecyclic group or optionally substituted lower alkynyl, R 2 is amidated carboxy, R 3 is hydrogen or acyl, Ar is aryl or heterocyclic group, X is thia, sulfinyl or sulfonyl, Y and Z are each lower alkylene, m and n are each an integer of 0 to 2, and a salt thereof, useful as inhibitors of matrix metalloproteinases (MMP) or the production of tumor necrosis factor &agr; (TNF &agr;).

  式(I)的化合物，其中R1是卤素、低碳氧基、可选取代芳基、可选取代芳氧基、可选取代杂环基或可选取代低炔基，R2是酰胺化羧基，R3是氢或酰基，Ar是芳基或杂环基，X是硫代、亚砜基或磺酰基，Y和Z是各自的低碳链基，m和n分别是0到2的整数，以及其盐，用作基质金属蛋白酶（MMP）抑制剂或肿瘤坏死因子α（TNFα）的产生。
• [EN] THIAZEPINYL HYDROXAMIC ACID DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS<br/>[FR] DERIVES DE L'ACIDE THIAZEPINYLHYDROXAMIQUE EN TANT QU'INHIBITEURS DES METALLOPROTEINASES MATRICIELLES
  申请人：FUJISAWA PHARMACEUTICAL CO

  公开号：WO2001060808A1

  公开（公告）日：2001-08-23

  A compound of formula (I) in which R1 is halo, lower alkoxy, optionally substituted aryl, optionally substituted aryloxy, optionally substituted heterecyclic group or optionally substituted lower alkynyl, R2 is amidated carboxy, R3 is hydrogen or acyl, Ar is aryl or heterocyclic group, X is thia, sulfinyl or sulfonyl, Y and Z are each lower alkylene, m and n are each an integer of 0 to 2, and a salt thereof, useful as inhibitors of matrix metalloproteinases (MMP) or the production of tumor necrosis factor α (TNF α).

  化合物的化学式为（I），其中R1为卤素，较低的烷氧基，可选取代芳基，可选取代芳氧基，可选取代杂环基或可选取代较低的炔基，R2为酰胺化的羧基，R3为氢或酰基，Ar为芳基或杂环基，X为硫代基，亚砜基或磺酰基，Y和Z均为较低的烷基，m和n均为0到2的整数，以及其盐，用作基质金属蛋白酶（MMP）或肿瘤坏死因子α（TNFα）的抑制剂。
• Oxadiazole compounds
  申请人：REMYND NV

  公开号：US10562869B2

  公开（公告）日：2020-02-18

  The present invention relates to a compound of formula (I) or (II) or a stereoisomer, enantiomer, racemic, or tautomer thereof, (I) (II) wherein R1, R2, R3, L1, L2, L3, L4, L5 and n, have the same meaning as that defined in the claims and the description. The present invention also relates to compositions, in particular pharmaceuticals, comprising such compounds, and to uses of such compounds and compositions for the prevention and/or treatment of metabolic disorders and/or neurodegenerative diseases, and/or protein misfolding disorders.

  本发明涉及式(I)或(II)化合物或其立体异构体、对映体、外消旋体或同系物，(I)(II) 其中R1、R2、R3、L1、L2、L3、L4、L5和n与权利要求和说明中定义的含义相同。本发明还涉及包含此类化合物的组合物，特别是药物，以及此类化合物和组合物在预防和/或治疗代谢紊乱和/或神经退行性疾病和/或蛋白质错误折叠紊乱方面的用途。